Medical News

[ Nordic Market Access, Pricing Reimbursement Conference 8-9 May 2012, Stockholm, Sweden ]

Nordic Market Access, Pricing Reimbursement Conference 8-9 May 2012, Stockholm, Sweden

This conference is the only event looking directly at ongoing reforms regarding pricing, reimbursement and funding of drugs specifically for the Nordic countries. Payers and HTAs will discuss how they are appraising health technologies, defining value, making reimbursement decisions, and following these up in practice. Leading pharma companies will present case study experiences of how they addressed challenges in delivering value to Nordic payers and engaging with the region's most important stakeholders. Those attending this meeting will understand the complete and up to date picture of the real market access environment in this region, and have a unique opportunity to network with the region's experts, with the goal of enhancing patient access to valued medicines. Why attend? Hear what current trends are influencing the highly innovative Nordic regions.

Health 2.0 Europe 2012 Conference, 6-7 November, Berlin

Now accepting applications to present. "THE Health 2.0 event in Europe - a must-attend event for any health 2.0 entrepreneur." Lukas Zinnagl, Co-founder & Editor MedCrunch, Austria "Health 2.0 Europe is 'sexy' and well executed! I met many interesting people and the event has greatly increased incoming queries to iDoc24! " Alexander Borve, CEO iDoc24, Sweden The 2nd annual Health 2.0 Europe sure created a lot of buzz. Over 50 speakers from all around the world 30 technology live demos / 4 product launches Participants from more than 25 countries 6 new Health 2.0 chapters in Europe: Amsterdam, Barcelona, Berlin, Helsinki, London, Moscow, and Stockholm! What is Health 2.0 Europe about? It's about a new generation of entrepreneurs believing they can be the change they want to see in their health systems.

'Bath Salts' The New Street Drug Mimicks The Effects Of 2 Powerful Narcotics

The street drug commonly referred to as "bath salts" is one of a growing list of synthetic and unevenly regulated narcotics that are found across the United States and on the Internet. New research on this potent drug paints an alarming picture, revealing that bath salts pack a powerful double punch, producing combined effects similar to both methamphetamine (METH) and cocaine. "This combination of effects is particularly novel and unexpected, " said Louis J. De Felice of Virginia Commonwealth University's School of Medicine in Richmond. "Methamphetamine and cocaine operate in the brain in completely opposite ways. It would be atypical that both drugs would be taken together, but that's the effect that occurs with bath salts." De Felice and his colleagues will present their research at the 56th Annual Meeting of the Biophysical Society (BPS), held Feb.

Eyeforpharma's Clinical Commercial Summit, 8-9 May 2012, Zurich

For 2012 R&D activities and budgets are being scrutinised, tough questions asked. Your products must show true commercial and clinical value. Innovation is now part of a business plan and the development activities and approval processes reflect that. Are you prepared for the challenge? Benchmark yourself against the industry leaders at the Clinical Commercial conference, 8th and 9th May, Zurich. Find out which companies are succeeding. They have worked towards a converged clinical and commercial focus. Their cross functional teams are working together to achieve sustainable innovation, deliver value and innovate towards un-met need. Join us and learn how to succeed: Build commercial endpoints into clinical trials - Novartis and the best of big pharma share how payer insight has provided robust development plans.

Late Phase Drug Development World Americas Conference 20-22 March 2012, Boston

The 3rd annual Late Phase Drug Development World Americas is fast approaching and promises to be better than ever this year, with great speakers and a packed agenda. Benchmark your late phase strategy alongside the industry's best Reasons to attend include: Comprehensive agenda - we have over 20 unique and informative sessions, keep track on our website for developments Pfizer, Novartis, AstraZeneca, Abbott, Eli Lilly & Co, Bayer, Takeda, Boehringer-Ingelheim and Johnson & Johnson - hear industry insights from our expert speaker panel! Quality content - we listen to you and your peers to ensure our program confronts the topics you want to hear Case studies - hear therapeutic area specific presentations, including Cardiovascular, Multiple Sclerosis, Infectious Disease, Oncology Extensive global reach - We have speakers that have worked extensively in the international landscape Pre conference workshop, focused networking sessions, panel discussions, delegate led questions.


Medical News © Nanda
Designer Damodar